Brilaroxazine, Reviva Pharmaceuticals’ experimental therapy for idiopathic pulmonary fibrosis (IPF), was found to reduce lung inflammation and fibrosis, or scarring, in a rat model of the disease. The treatment also improved lung function and extended survival in the animals, the study showed. Titled “Evaluation of Brilaroxazine (RP5063)…
An experimental oral medication Bristol Myers Squibb is developing did better than a placebo at slowing lung function decline for up to 26 weeks, slightly more than six months, in people with idiopathic pulmonary fibrosis (IPF). The effect was seen when the therapy, BMS-986278, was given at a…
Researchers have discovered a variant of the usual basal stem cells found in the lungs that may contribute to scarring, or fibrosis, in people with idiopathic pulmonary fibrosis (IPF) — and which may be a therapeutic target to slow disease progression. The team found that these basal stem cells,…
A high dose of bexotegrast, an oral treatment being developed by Pliant Therapeutics, continues to be well-tolerated for up to about nine months, with no serious side effects in people with idiopathic pulmonary fibrosis (IPF), according to long-term data from a Phase 2a trial. Six-month data from the…
AP02, an inhaled formulation of nintedanib being developed by Avalyn Pharma, was well tolerated by both healthy people and individuals with idiopathic pulmonary fibrosis (IPF) who took part in a Phase 1 clinical trial. The open-label study (ACTRN12620001141932) was designed to test the safety and tolerability…
AP01, Avalyn Pharma’s pirfenidone solution for inhalation, may have fewer side effects than the oral formulation now used to treat idiopathic pulmonary fibrosis (IPF) — while helping keep lung function from declining as quickly. That’s according to data from the company-sponsored Phase 1b ATLAS trial (ACTRN12618001838202), which…
KIN001, an experimental oral treatment of idiopathic pulmonary fibrosis (IPF), was more effective than Esbriet (pirfenidone) at easing lung fibrosis in a mouse model of the disease, its developer, Kinarus Therapeutics, reported. When KIN001 was given with Esbriet, an approved treatment, the reduction in fibrosis was even greater than…
Bellerophon Therapeutics has gotten the green light to cut by about half the number of patients who may enter REBUILD, its ongoing Phase 3 trial of INOpulse (inhaled nitric oxide) for the treatment of pulmonary hypertension linked to pulmonary fibrosis. The downsizing may help the company complete the…
Algernon Pharmaceuticals has filed for orphan drug status for NP-120 (ifenprodil), an experimental oral medicine for patients with idiopathic pulmonary fibrosis (IPF) who have persistent, hard-to-treat cough. “The FDA has a standard response time of 90 days to requests for orphan designation, and so we should know by…
A molecular test, called the Envisia Genomic Classifier, may predict which patients with idiopathic pulmonary fibrosis (IPF) will progress on immunosuppressants, which could help doctors decide who will more likely benefit from antifibrotic therapy. The test, developed by Veracyte, can tell IPF from other types of interstitial lung…
Get regular updates to your inbox.
